Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gujarat Kidney And Super SpecialityNSE:GKSL -0.99%18 Return-on-Tangible-Equity is 12.47% as of Mar. 2026, which is 62% below its 10-year median of 32.62. GuruFocus rates NSE:GKSL with a GF Score™ of 18/100. The stock has 5 warning signs investors should review. Among 580 Healthcare Providers & Services companies, Gujarat Kidney And Super Speciality ranks better than 67.93% on this metric.
The historical rank and industry rank for Gujarat Kidney And Super Speciality's Return-on-Tangible-Equity or its related term are showing as below:
NSE:GKSL'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 16.03 Med: 32.62 Max: 43.79
Current: 20.33
During the past 4 years, Gujarat Kidney And Super Speciality's highest Return-on-Tangible-Equity was 43.79%. The lowest was 16.03%. And the median was 32.62%.
NSE:GKSL's Return-on-Tangible-Equity is ranked better than 67.93% of 580
companies
in the Healthcare Providers & Services industry
Industry Median: 10.085
vs NSE:GKSL: 20.33
Gujarat Kidney And Super Speciality (NSE:GKSL) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Gujarat Kidney And Super Speciality Return-on-Tangible-Equity Related Terms
Gujarat Kidney And Super Speciality Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gujarat Kidney And Super Speciality Return-on-Tangible-Equity Chart
Gujarat Kidney And Super Speciality Annual Data
Trend
Mar23
Mar24
Mar25
Mar26
Return-on-Tangible-Equity
30.22
43.79
35.01
16.03
Gujarat Kidney And Super Speciality Quarterly Data
NSE:GKSL vs HCA, THC, DVA: Return-on-Tangible-Equity Comparison
For the Medical Care Facilities subindustry, Gujarat Kidney And Super Speciality's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gujarat Kidney And Super Speciality Return-on-Tangible-Equity vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Gujarat Kidney And Super Speciality's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Gujarat Kidney And Super Speciality's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 12.47% mean?
Gujarat Kidney And Super Speciality (NSE:GKSL) has a Return-on-Tangible-Equity of 12.47% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Gujarat Kidney And Super Speciality and its competitors. This is 62% below median its historical median of 32.62. Over the past decade, Gujarat Kidney And Super Speciality's Return-on-Tangible-Equity has ranged from 16.03 to 43.79. According to the industry distribution chart, Gujarat Kidney And Super Speciality ranks #186 out of 580 companies in the Healthcare Providers & Services industry, placing it in the top 32.1%.
Is Gujarat Kidney And Super Speciality's Return-on-Tangible-Equity too high?
Gujarat Kidney And Super Speciality's current Return-on-Tangible-Equity of 12.47% is 62% below median its 10-year median of 32.62. Over the past 10 years, this metric has ranged from a low of 16.03 to a high of 43.79. The Healthcare Providers & Services industry median Return-on-Tangible-Equity is 10.09. Gujarat Kidney And Super Speciality's value of 12.47% is 23.6% above this industry median. Based on the distribution chart, Gujarat Kidney And Super Speciality ranks #186 out of 580 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Gujarat Kidney And Super Speciality has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Gujarat Kidney And Super Speciality's Return-on-Tangible-Equity compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Gujarat Kidney And Super Speciality ranks #186 out of 580 companies for Return-on-Tangible-Equity. This puts Gujarat Kidney And Super Speciality in the upper half of its industry. The industry median Return-on-Tangible-Equity is 10.09. Gujarat Kidney And Super Speciality's value of 12.47% is 23.6% above this benchmark. Historically, Gujarat Kidney And Super Speciality's own Return-on-Tangible-Equity has ranged from 16.03 to 43.79 over the past decade. While the company's 10-year median is 32.62 vs. the industry median of 10.09, Gujarat Kidney And Super Speciality has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Healthcare Providers & Services company?
The median Return-on-Tangible-Equity among Healthcare Providers & Services companies is 10.09, based on 580 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gujarat Kidney And Super Speciality's current Return-on-Tangible-Equity of 12.47% is 23.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Gujarat Kidney And Super Speciality and its competitors. For the Healthcare Providers & Services industry, the median Return-on-Tangible-Equity is 10.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gujarat Kidney And Super Speciality's current Return-on-Tangible-Equity is 12.47%, which is 62% below median its own 10-year median of 32.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gujarat Kidney And Super Speciality stock overvalued right now?
Gujarat Kidney And Super Speciality (NSE:GKSL) has a current Return-on-Tangible-Equity of 12.47%. The current Return-on-Tangible-Equity is 12.47%, which is 62% below median its 10-year median of 32.62 and 23.6% above the Healthcare Providers & Services industry median of 10.09. Gujarat Kidney And Super Speciality's overall GF Score™ is 18/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Gujarat Kidney And Super Speciality (NSE:GKSL), the current Return-on-Tangible-Equity is 12.47% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Gujarat Kidney And Super Speciality Business Description
Gujarat Kidney And Super Speciality Ltd is engaged in the business of operating a chain of mid-sized multispeciality hospitals in central Gujarat and providing integrated healthcare services, with a focus on secondary and tertiary care. It offers a range of healthcare services, including General Medicine, General Surgery, Laparoscopic Surgery, Urology, Cardiology, Nephrology, and many more. The company operates in a single segment, namely Medical and Healthcare Services. It generates a substantial portion of revenue from its services to inpatients. Geographically, it operates only in India.
18GF Score
Get the complete analysis for NSE:GKSL
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:GKSL has been successfully added to your 
